A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 5, Issue 4, 2009, Pages 419-423

  Zhou, Qinghua ^a,b   Sun, Xun ^a   Zeng, Lingyuan ^c   Liu, Jie ^a   Zhang, Zhirong ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b SICHUAN UNIVERSITY   (China)

^c SICHUAN CANCER HOSPITAL   (China)

Author keywords

Mitoxantrone; Phase II clinical trial; Polybutylcyanacrylate nanoparticles; Unresected hepatocellular carcinoma

Indexed keywords

CLINICAL TRIAL; HEPATOCELLULAR CARCINOMA; MITOXANTRONE; PHASE II; POLYBUTYLCYANACRYLATE NANOPARTICLES;

FLUORINE CONTAINING POLYMERS; ONCOLOGY; TUMORS;

NANOPARTICLES;

HEMOGLOBIN; MITOXANTRONE; NANOPARTICLE; POLYBUTYLCYANACRYLIC ACID; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER GROWTH; CANCER SURVIVAL; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOTOXICITY; DIARRHEA; DRUG FATALITY; FEMALE; HEART DISEASE; HUMAN; KIDNEY FAILURE; LEUKOCYTE; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NANOENCAPSULATION; NAUSEA AND VOMITING; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE; TREATMENT RESPONSE;

ADULT; AGED; ALPHA-FETOPROTEINS; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MITOXANTRONE; NANOMEDICINE; NANOPARTICLES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70749160131     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2009.01.009     Document Type: Article

References (17)

1. Nowak A.K., Chow P.K., and Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer 40 (2004) 1474-1484
2. Leung T.W., Yu S., Johnson P.J., Geschwind J., Vogl T.J., Engelmann K., et al. Phase II study of the efficacy and safety of cisplatin epinephrine injectable gel administered to patients with unresectable hepatocellular carcinoma. J Clin Oncol 4 (2003) 652-658
3. Kim K.Y. Nanotechnology platforms and physiological challenges for cancer therapeutics. Nanomedicine 3 (2007) 103-110
4. Fernandez-Urrusuno R., Fattal E., Porquet D., Feger J., and Couvereur P. Evaluation of liver toxicological effects induced by polyalkylcyanoacrylate nanoparticles. Toxicol Appl Pharmocol 130 (1995) 272-279
5. Shenkenberg T.D., and Von Hoff D.D. Mitoxantrone: a new anti-cancer drug with significant clinical activity. Ann Intern Med 105 (1986) 67-81
6. Zhang Z.R., Liao G.T., Nagai T., and Hou S.X. Mitoxantrone polybutyl cyanoacrylate nanoparticles as an anti-neoplastic targeting drug delivery system. Int J Pharm 139 (1996) 1-8
7. Zhang Z.R., He Q., Liao G.T., and Bai S.H. Study on liver targeting and hepatocytes permeable valaciclovir polybutylcyanoacrylate nanoparticles. World J Gastroenterol 5 (1999) 511-514
8. World Health Organization (WHO). WHO toxicity criteria by grade. http://www.accessdata.fda.gov/scripts/cder/onctools/whotox.cfm
9. Guan Z., Wang Y., Maoleekoonpairoj S., Chen Z., Kim W.S., Ratanatharathorn V., et al. Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. Br J Cancer 89 (2003) 1865-1869
10. Colleoni M., Buzzoni R., Bajetta E., Bochicchio A.M., Bartoli C., Audisio R., et al. A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma. Cancer 72 (1993) 3196-3201
11. Jones Jr. D.V., Patt Y.Z., Ajani J.A., Abbruzzese J., Carrasco C.H., Charnsangavej C., et al. A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. Cancer 72 (1993) 2560-2563
12. Zhang Z.R., and He Q. Study on liver targeting and hepatocytes permeable valaciclovir polybutylcyanoacrylate nanoparticles. World J Gastroenterol 5 (1999) 330-333
13. Sun X., Wu F., Lu W., and Zhang Z.R. Study on liver targeting and sustained release hydroxycanptothecin polybutylcyanoacrylate nanoparticles. Pharmazie 59 (2004) 791-794
14. Zimmer A. Antisense oligonucleotide delivery with polyhexylcyanoacrylate nanoparticles as carriers. Methods 18 (1999) 286-295
15. Kreuter J. Drug targeting with nanoparticles. Eur J Drug Metab Pharmacokinet 19 (1994) 253-256
16. Kattan J., Droz P., Couvreur P., Marino P., Boutan-Laroze A., Rougier P., et al. Polyisobutylcyanoacrylate nanoparticles as drug carriers: influence of sulfur dioxide on the physico-chemical characteristics of ciprofloxacin-and doxorubicin-loaded nanoparticles. Invest New Drugs 10 (1992) 191-199
17. Falkson G., Ryan M., Johnson A., Simson W., Goetzer J., Carbone P., et al. A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma: an ECOG study. Cancer 60 (1987) 2141-2145